초록 ▼

The present invention provides a method and a composition for preserving a virus. The virus is placed in a liquid carrier with a stabilizing agent selected from the group consisting of polysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, and combinations thereof. The liquid composition can b

The present invention provides a method and a composition for preserving a virus. The virus is placed in a liquid carrier with a stabilizing agent selected from the group consisting of polysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, and combinations thereof. The liquid composition can be maintained at a temperature above 0° C. for a significant period of time while maintaining a satisfactory degree of viral activity.

대표청구항 ▼

The present invention provides a method and a composition for preserving a virus. The virus is placed in a liquid carrier with a stabilizing agent selected from the group consisting of polysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, and combinations thereof. The liquid composition can b

The present invention provides a method and a composition for preserving a virus. The virus is placed in a liquid carrier with a stabilizing agent selected from the group consisting of polysorbate 80, L-arginine, polyvinylpyrrolidone, trehalose, and combinations thereof. The liquid composition can be maintained at a temperature above 0° C. for a significant period of time while maintaining a satisfactory degree of viral activity. Peptides Presented by HLA-A2," Cell, 75:693-708, Nov. 1993. Marincola et al., "HLA Association with Response and Toxicity in Melanoma Patients Treated with Interleukin 2-based Immunotherapy," Cancer Research, 52:6561-6566, Dec. 1992. Parker et al., "Sequence Motifs Important for Peptide Binding to the Human MHC Class I Molecule, HLA-A2," The Journal of Immunology, 149(11):3580-3587, Dec. 1992. Ratner and Clark, "Role of TNG-α in CD8° Cytotoxic T Lymphocyte-Mediated Lysis," The Journal of Immunology, 150(10):4303-4314, May 1993. Schmidt et al., "Oligopeptide Induction of a Seconary Cytotoxic T-cell Response to Esptein-Barr Virus In Vitro," Scand. J. Immunol., 33:411-420, 1991. Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer," Science, 244:707-712, May 1989. Suhrbier et al., "Peptide Epitope Induced Apoptosis of Human Cytotoxic T Lymphocytes," The Journal of Immunology, 159(6): 2169-2178, Mar. 1993. Wolfel et al., "Lysis of Human Pancreatic Adenocarcinoma Cells by Autologous HLA-Class I-Restricted Cytolytic T-Lymphocyte (CTL) Clones," Int. J. Cancer, 54:636-644, 1993. Zweerink et al., "Presentation of Endogenous Peptides to MHC Class I-Restricted Cytotoxic T Lymphocytes in Transport Deletion Mutant T2 Cells," The Journal of Immunology, 150(5):1763-1771, Mar. 1993. more amino acid substitutions at positions analogous to amino acids 100-108 of SEQ ID NO:2. 6. The polypeptide of claim 1, wherein said polypeptide consists of an amino acid sequence having a glycine to serine substitution at amino acid 99 in the amino acid sequence of SEQ ID NO:2. 7. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier. 8. A purified polypeptide comprising a mutant amino acid sequence of SEQ ID NO:2, wherein said polypeptide comprises one or more amino acid substitutions at amino acid positions corresponding to residues 99-108 of SEQ ID NO:2, provided that an amino acid residue in said polypeptide at an amino acid corresponding to position 99 of SEQ ID NO:2 is other than glycine. 9. A polypeptide of claim 8, wherein the amino acid residue at position 99 is a serine. 10. A purified polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NO:5, provided that an amino acid residue in said polypeptide at an amino acid analogous to position 100 of SEQ ID NO:5 is other than glycine. 11. The polypeptide of claim 10, wherein said residue is a substrate for a kinase activity. 12. The polypeptide of claim 11, wherein said residue is serine. 13. The polypeptide of claim 10, wherein said polypeptide comprises an amino acid sequence at least 90% identical to SEQ ID NO:5. 14. The polypeptide of claim 10, said polypeptide further comprising one or more amino acid substitutions at positions analogous to amino acids 101-109 of SEQ ID NO:5. 15. The polypeptide of claim 10, wherein said polypeptide comprises an amino acid sequence having a glycine to serine substitution at amino acid 100 in the amino acid sequence of SEQ ID NO:5. 16. A purified polypeptide comprising a mutant amino acid sequence of SEQ ID NO:5, wherein said polypeptide comprises one or more amino acid substitutions at amino acid positions corresponding to residues 100-109 of SEQ ID NO: 5, provided that an amino acid residue in said polypeptide at an amino acid corresponding to position 100 of SEQ ID NO:5 is other than glycine. 17. A polypeptide of claim 16, wherein the amino acid residue at position 100 is a serine. 18. A composition comprising the polypeptide of claim 10 and a pharmaceutically acceptable carrier.